Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CLOV vs MOH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CLOV
Clover Health Investments, Corp.

Medical - Healthcare Plans

HealthcareNASDAQ • US
Market Cap$1.37B
5Y Perf.-74.8%
MOH
Molina Healthcare, Inc.

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$10.28B
5Y Perf.+7.8%

CLOV vs MOH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CLOV logoCLOV
MOH logoMOH
IndustryMedical - Healthcare PlansMedical - Healthcare Plans
Market Cap$1.37B$10.28B
Revenue (TTM)$2.21B$45.08B
Net Income (TTM)$-57M$188M
Gross Margin42.5%9.6%
Operating Margin-2.6%1.2%
Forward P/E65.9x37.2x
Total Debt$0.00$3.95B
Cash & Equiv.$78M$4.25B

CLOV vs MOHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CLOV
MOH
StockJun 20May 26Return
Clover Health Inves… (CLOV)10025.2-74.8%
Molina Healthcare, … (MOH)100107.8+7.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: CLOV vs MOH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MOH leads in 3 of 6 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Clover Health Investments, Corp. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
CLOV
Clover Health Investments, Corp.
The Insurance Pick

CLOV is the clearest fit if your priority is growth exposure.

  • Rev growth 40.3%, EPS growth -93.6%, 3Y rev CAGR 20.6%
  • 40.3% revenue growth vs MOH's 11.7%
  • -20.0% vs MOH's -37.6%
Best for: growth exposure
MOH
Molina Healthcare, Inc.
The Insurance Pick

MOH carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.

  • 334.0% 10Y total return vs CLOV's -73.7%
  • Lower volatility, beta -0.04, Low D/E 97.1%, current ratio 1.69x
  • Beta -0.04, current ratio 1.69x
Best for: long-term compounding and sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthCLOV logoCLOV40.3% revenue growth vs MOH's 11.7%
ValueMOH logoMOHLower P/E (37.2x vs 65.9x)
Quality / MarginsMOH logoMOHCombined ratio 1.0 vs CLOV's 1.0 (lower = better underwriting)
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)CLOV logoCLOV-20.0% vs MOH's -37.6%
Efficiency (ROA)MOH logoMOH1.2% ROA vs CLOV's -9.6%, ROIC 17.4% vs -34.0%

CLOV vs MOH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CLOVClover Health Investments, Corp.
FY 2025
Insurance Segment
100.0%$50M
MOHMolina Healthcare, Inc.
FY 2025
Medicaid Solutions Segment
74.7%$32.2B
Medicare
14.5%$6.2B
Marketplace
10.4%$4.5B
Other Segments
0.4%$177M

CLOV vs MOH — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCLOVLAGGINGMOH

Income & Cash Flow (Last 12 Months)

CLOV leads this category, winning 3 of 5 comparable metrics.

MOH is the larger business by revenue, generating $45.1B annually — 20.4x CLOV's $2.2B. Profitability is closely matched — net margins range from 0.4% (MOH) to -2.6% (CLOV). On growth, CLOV holds the edge at +62.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCLOV logoCLOVClover Health Inv…MOH logoMOHMolina Healthcare…
RevenueTrailing 12 months$2.2B$45.1B
EBITDAEarnings before interest/tax-$55M$710M
Net IncomeAfter-tax profit-$57M$188M
Free Cash FlowCash after capex$55M$251M
Gross MarginGross profit ÷ Revenue+42.5%+9.6%
Operating MarginEBIT ÷ Revenue-2.6%+1.2%
Net MarginNet income ÷ Revenue-2.6%+0.4%
FCF MarginFCF ÷ Revenue+2.5%+0.6%
Rev. Growth (YoY)Latest quarter vs prior year+62.0%-3.1%
EPS Growth (YoY)Latest quarter vs prior year-95.0%
CLOV leads this category, winning 3 of 5 comparable metrics.

Valuation Metrics

MOH leads this category, winning 3 of 4 comparable metrics.
MetricCLOV logoCLOVClover Health Inv…MOH logoMOHMolina Healthcare…
Market CapShares × price$1.4B$10.3B
Enterprise ValueMkt cap + debt − cash$1.3B$10.0B
Trailing P/EPrice ÷ TTM EPS-15.76x22.13x
Forward P/EPrice ÷ next-FY EPS est.65.89x37.20x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple10.23x
Price / SalesMarket cap ÷ Revenue0.71x0.23x
Price / BookPrice ÷ Book value/share4.49x2.46x
Price / FCFMarket cap ÷ FCF
MOH leads this category, winning 3 of 4 comparable metrics.

Profitability & Efficiency

MOH leads this category, winning 6 of 7 comparable metrics.

MOH delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-17 for CLOV. On the Piotroski fundamental quality scale (0–9), MOH scores 4/9 vs CLOV's 2/9, reflecting mixed financial health.

MetricCLOV logoCLOVClover Health Inv…MOH logoMOHMolina Healthcare…
ROE (TTM)Return on equity-17.1%+4.4%
ROA (TTM)Return on assets-9.6%+1.2%
ROICReturn on invested capital-34.0%+17.4%
ROCEReturn on capital employed-24.5%+9.8%
Piotroski ScoreFundamental quality 0–924
Debt / EquityFinancial leverage0.97x
Net DebtTotal debt minus cash-$78M-$298M
Cash & Equiv.Liquid assets$78M$4.2B
Total DebtShort + long-term debt$0$4.0B
Interest CoverageEBIT ÷ Interest expense2.12x
MOH leads this category, winning 6 of 7 comparable metrics.

Total Returns (Dividends Reinvested)

CLOV leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in MOH five years ago would be worth $7,490 today (with dividends reinvested), compared to $3,256 for CLOV. Over the past 12 months, CLOV leads with a -20.0% total return vs MOH's -37.6%. The 3-year compound annual growth rate (CAGR) favors CLOV at 45.1% vs MOH's -12.5% — a key indicator of consistent wealth creation.

MetricCLOV logoCLOVClover Health Inv…MOH logoMOHMolina Healthcare…
YTD ReturnYear-to-date+11.2%+10.6%
1-Year ReturnPast 12 months-20.0%-37.6%
3-Year ReturnCumulative with dividends+205.7%-33.1%
5-Year ReturnCumulative with dividends-67.4%-25.1%
10-Year ReturnCumulative with dividends-73.7%+334.0%
CAGR (3Y)Annualised 3-year return+45.1%-12.5%
CLOV leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CLOV and MOH each lead in 1 of 2 comparable metrics.

MOH is the less volatile stock with a -0.04 beta — it tends to amplify market swings less than CLOV's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLOV currently trades 68.4% from its 52-week high vs MOH's 59.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCLOV logoCLOVClover Health Inv…MOH logoMOHMolina Healthcare…
Beta (5Y)Sensitivity to S&P 5001.22x-0.04x
52-Week HighHighest price in past year$3.92$333.00
52-Week LowLowest price in past year$1.58$121.06
% of 52W HighCurrent price vs 52-week peak+68.4%+59.3%
RSI (14)Momentum oscillator 0–10067.074.7
Avg Volume (50D)Average daily shares traded5.6M1.4M
Evenly matched — CLOV and MOH each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates CLOV as "Hold" and MOH as "Buy". Consensus price targets imply 24.3% upside for CLOV (target: $3) vs -15.9% for MOH (target: $166).

MetricCLOV logoCLOVClover Health Inv…MOH logoMOHMolina Healthcare…
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$3.33$166.09
# AnalystsCovering analysts938
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+4.0%+9.7%
Insufficient data to determine a leader in this category.
Key Takeaway

CLOV leads in 2 of 6 categories (Income & Cash Flow, Total Returns). MOH leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.

Best OverallClover Health Investments, … (CLOV)Leads 2 of 6 categories
Loading custom metrics...

CLOV vs MOH: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is CLOV or MOH a better buy right now?

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 11. 7% for Molina Healthcare, Inc. (MOH). Molina Healthcare, Inc. (MOH) offers the better valuation at 22. 1x trailing P/E (37. 2x forward), making it the more compelling value choice. Analysts rate Molina Healthcare, Inc. (MOH) a "Buy" — based on 38 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CLOV or MOH?

On forward P/E, Molina Healthcare, Inc.

is actually cheaper at 37. 2x.

03

Which is the better long-term investment — CLOV or MOH?

Over the past 5 years, Molina Healthcare, Inc.

(MOH) delivered a total return of -25. 1%, compared to -67. 4% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: MOH returned +306. 6% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CLOV or MOH?

By beta (market sensitivity over 5 years), Molina Healthcare, Inc.

(MOH) is the lower-risk stock at -0. 04β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately -3434% more volatile than MOH relative to the S&P 500.

05

Which is growing faster — CLOV or MOH?

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus 11. 7% for Molina Healthcare, Inc. (MOH). On earnings-per-share growth, the picture is similar: Molina Healthcare, Inc. grew EPS -56. 3% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CLOV or MOH?

Molina Healthcare, Inc.

(MOH) is the more profitable company, earning 1. 0% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MOH leads at 1. 7% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CLOV or MOH more undervalued right now?

On forward earnings alone, Molina Healthcare, Inc.

(MOH) trades at 37. 2x forward P/E versus 65. 9x for Clover Health Investments, Corp. — 28. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 24. 3% to $3. 33.

08

Which pays a better dividend — CLOV or MOH?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is CLOV or MOH better for a retirement portfolio?

For long-horizon retirement investors, Molina Healthcare, Inc.

(MOH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 04), +306. 6% 10Y return). Both have compounded well over 10 years (MOH: +306. 6%, CLOV: -72. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CLOV and MOH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CLOV is a small-cap high-growth stock; MOH is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CLOV

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 31%
  • Gross Margin > 25%
Run This Screen
Stocks Like

MOH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CLOV and MOH on the metrics below

Revenue Growth>
%
(CLOV: 62.0% · MOH: -3.1%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.